2022
Systemic Manifestations of Gastrointestinal Tract Diseases and Systemic Diseases Involving the Gastrointestinal Tract
Patel N, Das P, Jain D. Systemic Manifestations of Gastrointestinal Tract Diseases and Systemic Diseases Involving the Gastrointestinal Tract. 2022, 521-572. DOI: 10.1007/978-981-16-6395-6_14.Peer-Reviewed Original ResearchExtraintestinal manifestationsGastrointestinal disordersSystemic diseaseGastrointestinal tractPrimary gastrointestinal disordersCommon gastrointestinal disorderInflammatory bowel diseaseCommon systemic diseasesGastrointestinal tract diseaseGastrointestinal symptomsBowel diseaseRenal diseaseSystemic manifestationsVasculitic disordersWhipple's diseaseSystemic disordersVascular diseaseCeliac diseaseGastrointestinal infectionsTract diseasePathogenetic mechanismsPolyposis syndromeGastrointestinal diseasesPancreatic diseaseDisease
2015
A Nodular Foreign Body Reaction in a Dialysis Patient Receiving Long-term Treatment With Lanthanum Carbonate
Valika AK, Jain D, Jaffe PE, Moeckel G, Brewster UC. A Nodular Foreign Body Reaction in a Dialysis Patient Receiving Long-term Treatment With Lanthanum Carbonate. American Journal Of Kidney Diseases 2015, 67: 128-132. PMID: 26385816, DOI: 10.1053/j.ajkd.2015.07.033.Peer-Reviewed Case Reports and Technical NotesConceptsEnd-stage renal diseaseLanthanum carbonate treatmentUpper gastrointestinal bleedSimilar pathologic findingsLong-term treatmentCollections of histiocytesForeign body reactionGastrointestinal bleedGastrointestinal bleedingUpper endoscopyDialysis patientsHIV infectionRenal diseaseComorbid conditionsPathologic findingsAdverse reactionsHyperechoic materialEndoscopic ultrasoundHyperplastic epitheliumPhosphate bindersGiant cellsLanthanum carbonateGranular cytoplasmic materialPatientsBody reaction
2009
HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin
Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, Friedman A, Jain D, Bia M, Formica R, Mehal W. HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin. Journal Of Clinical Gastroenterology 2009, 43: 477-481. PMID: 19142165, PMCID: PMC3715868, DOI: 10.1097/mcg.0b013e318180803a.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseHepatitis C virusCombination therapyRenal diseasePosttreatment rateSide effectsSerious adverse side effectsDose of ribavirinNon-ESRD patientsSafe therapeutic optionEarly virologic responseProspective observational studyMonths of treatmentStage renal diseaseCases of anemiaInitial response rateLength of treatmentInterferon α-2aAdverse side effectsPO weeklyVirologic responseESRD patientsHCV infectionESRD populationHCV response